Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Non-alcoholic fatty liver disease (NAFLD) is a severe hepatic health threat with no effective treatment. Based on the results that Chenopodium quinoa Willd. flavonoids eluted with 30% ethanol (CQWF30) can effectively alleviate NAFLD, this study employed ultrahigh-performance liquid chromatography-electrospray ionization-tandem mass spectrometry (UPLC-ESI-MS/MS) to analyze the components of CQWF30., and screened for flavonoids with potential NAFLD-mitigating effects through network pharmacology. In vitro models using HepG2 and BEL-7402 cell lines induced with free fatty acid (FFA) showed that isorhamnetin administration reduced intracellular lipid deposition and reversed elevated triglyceride (TG) and total cholesterol (T-CHO) levels. In vivo experiments in high-fat diet (HFD) mice demonstrated that isorhamnetin significantly lowered serum and liver fat content, mitigated liver damage, and modulated bile acid metabolism by upregulating FXR and BSEP and downregulating SLCO1B3. Consequently, isorhamnetin shows promise as a treatment for NAFLD due to its lipid-lowering and hepatoprotective activities.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11475887 | PMC |
| http://dx.doi.org/10.3390/foods13193076 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Two-Decade Trends in MASLD and Its Complications in the Middle East and North Africa (2010-2021).
Liver Int
October 2025
The Global NASH Council, Washington, DC, USA.
Background: The Middle East and North Africa (MENA) region is undergoing demographic shifts potentially increasing metabolic dysfunction-associated steatotic liver disease (MASLD) and its complications. We assessed MASLD prevalence and liver disease burden from 2010 to 2021.
Methods: Data from Global Burden of Disease (GBD), United Nations Population Division and NCD Risk Factor Collaboration covering 21 MENA countries were used for annual percent change (APC) trends per Joinpoint regression.
Investigating multimorbidity trajectories in people living with MASLD diagnosis: A trajectory analysis using the UK Biobank.
Diabetes Obes Metab
September 2025
Phase I Clinical Trial Research Ward, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, People's Republic of China.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging global health concern, and its presence increases the risk of multi-system diseases. This study aimed to investigate the multimorbidity trajectories of chronic diseases in people living with MASLD.
Methods: We identified 137 859 MASLD patients in UK Biobank and used 'propensity score matching' to match an equal number of non-MASLD controls.
The Triglyceride-Glucose Index Mediates the Association Between Obstructive Sleep Apnea and Non-Alcoholic Fatty Liver Disease: Findings From Two Cross-Sectional Datasets.
Diabetes Metab Syndr Obes
August 2025
Department of Otolaryngology, the Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, People's Republic of China.
Purpose: Obstructive sleep apnea (OSA) contributes to non-alcoholic fatty liver disease (NAFLD) via pathways involving insulin resistance (IR). The triglyceride-glucose (TyG) index, a widely used marker of IR, is associated with both OSA and NAFLD. However, the role of the TyG index in linking OSA to NAFLD remains underexplored.
View Article and Find Full Text PDFImpact of tenofovir entecavir treatment on progression of chronic hepatitis B: A nationwide cohort study.
JHEP Rep
October 2025
Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
Background & Aims: Conflicting evidence exists on hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis B (CHB) receiving tenofovir entecavir. We assessed the impacts of the two drugs on the clinical trajectory of CHB at a population level.
Methods: We conducted a retrospective nationwide cohort study using data from Taiwan's National Health Insurance Research Database, including 55,885 patients with CHB who were treatment-naïve aged 30-75 years receiving tenofovir (n = 17,137) or entecavir (n = 38,748) monotherapy for ≥3 months between November 2009 and December 2020, and followed until December 2022.
Broad-spectrum therapeutic potential of 4-phenylbutyrate in neurological and systemic diseases of viral and non-viral origin.
Front Pharmacol
August 2025
Department of Ophthalmology and Visual Sciences, University of Illinois Chicago, Chicago, IL, United States.
4-Phenylbutyrate (4-PBA), initially recognized for treating urea cycle disorders, has emerged as a potent therapeutic agent with broad-spectrum potential. As a chemical chaperone, 4-PBA modulates protein folding and reduces endoplasmic reticulum stress. 4-PBA has demonstrated efficacy in treating ocular herpes simplex virus type 1 (HSV-1) infection and HSV-1-induced encephalitis, highlighting its potential as a novel anti-herpetic therapy.
View Article and Find Full Text PDF